
    
      In the experimental group, patients received Camrelizumab injection (SHR-1210) 200mg d1, CIK
      cells 1x10^10 d14; Q3W, for 4 cycles; then Camrelizumab injection maintenance treatment for 2
      years. In the control group, patients received Camrelizumab injection 200mg d1, Q3W, for 2
      years.
    
  